Da behandlingsrelaterede forhøjelse af ASAT og/ eller ALAT er en markør for potentielt alvorlige leverskader, skal lever- aminotransferaseniveauer måles, inden behandlingen påbegyndes og derefter månedligt.
Because treatment-associated elevations of AST and/ or ALT are a marker for potential serious liver injury, liver aminotransferase levels must be measured prior to initiation of treatment and subsequently at monthly intervals.